Save the date! We invite you to join Oncology Nursing News for an #OncNurseConnect Tweet Chat on Wednesday, August 21.
Save the date! We invite you to join Oncology Nursing News for an #OncNurseConnect Tweet Chat on Wednesday, August 21, at 1 p.m. EST, when we plan on discussing popular topics in oncology nursing, including safe drug handling, burnout, adverse event management, and more.
#OncNurseConnect Q1: In an effort to provide the best care to patients, nurses may sometimes sacrifice their own safety by not wearing proper safety gear when handling chemotherapy drugs or even skipping lunch. Have you experienced this?
#OncNurseConnect Q2: Many nurses are quick to credit those who came before them for their success — have you ever worked with a mentor or served as a mentor for someone else in your unit?
#OncNurseConnect Q3: As an oncology nurse, you’re no doubt familiar with long shifts and stressful situations. Have you experienced burnout as a result of the demands of your job? How do you cope?
#OncNurseConnect Q4: While the treatment landscape continues to change for all cancer types, keeping up with potential AEs is key in helping patients obtain optimal outcomes. How do you keep up, and how do you communicate these to patients?
#OncNurseConnect Q5: The oncology space is constantly shifting - how do you stay current on the latest information in your field? Have you invested in any professional development or continuing education?
#OncNurseConnect Q6: We recently polled our social media audience about what matters most to them in their profession, and workplace safety was a hot topic, with a focus on workplace violence. Have you experienced this?
Never participated in a Tweet Chat before? It’s simple!
We’ll see you on Twitter!
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
Published: January 27th 2025 | Updated: January 28th 2025T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting.
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer
January 26th 2025While ctDNA positivity was linked to worse overall disease-free survival (DFS) in stage III resected colon cancer, it was associated with significantly improved DFS with celecoxib compared to placebo.